Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossCommercial · Coverage · Medical Policy · Oncology, Endocrinology, Gastroenterology +1 moreMedium impact

08.01.40i, Lanreotide (Somatuline Depot)

Act
by Sep 4, 2026
Effective date
Sep 4, 2026
Identified
Sep 5, 2026

Summary

Independence Blue Cross updated policy 08.01.40i to expand coverage of Lanreotide (Somatuline Depot) based on National Comprehensive Cancer Network (NCCN) guidelines. New covered indications include carcinoid syndrome, CNS sellar tumors, and multiple neuroendocrine tumor types (GI tract, lung, thymus, pancreas). Billing teams must verify diagnosis codes support medical necessity for expanded indications and ensure claims are submitted with appropriate ICD-10 codes.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

by Sep 4, 2026 · 5 steps
01Billing team must update claim submission protocols to recognize expanded coverage indications for Lanreotide (J1930, J1932).
02Review patient records to identify diagnoses now covered under this policy update: carcinoid syndrome, GH-secreting/TSH-secreting sellar tumors, GEP-NETs, and neuroendocrine tumors of GI tract/lung/thymus.
03Ensure ICD-10 diagnosis codes submitted with claims accurately reflect qualifying conditions per NCCN criteria listed in policy.
04Update billing system templates and prior authorization procedures to reflect new covered diagnoses.
05Communicate changes to providers and clinical staff.
If missed: Failure to submit appropriate supporting diagnosis codes may result in claim denials or delays.

Codes mentioned

J1930J1932

Original notice

08.01.40i, Lanreotide (Somatuline Depot)
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
MA08.090i, Lanreotide (Somatuline Depot)MediumEffective Sep 4, 2026 · Medical PolicyMA08.090h, Lanreotide (Somatuline® Depot)MediumEffective Nov 17, 2025 · Pharmacy08.01.40h, Lanreotide (Somatuline® Depot)MediumEffective Nov 17, 2025 · PharmacyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesOncologyEndocrinologyGastroenterologyPulmonologyCode J1930Code J1932

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account